Summary & Overview
HCPCS P9012: Cryoprecipitate, Each Unit
HCPCS Level II code P9012 designates a single unit of cryoprecipitate, a plasma-derived blood product rich in fibrinogen and clotting factors. Cryoprecipitate is an essential therapy for bleeding or coagulopathy related to low fibrinogen, certain inherited bleeding disorders, and during massive transfusion protocols. Nationally, accurate coding for cryoprecipitate affects hospital transfusion management, inventory tracking, and payer reimbursement for blood products.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for P9012, typical sites of service where the product is used, and the payers most commonly involved in coverage and claims adjudication. The publication summarizes billing benchmarks, common modifier usage patterns where available, and relevant policy considerations affecting coverage and billing for cryoprecipitate.
This summary is intended to inform billing professionals, hospital revenue cycle teams, and clinicians involved in transfusion services about the role of HCPCS Level II code P9012, common operational settings, and the payer landscape without providing clinical guidance or prescriptive recommendations.
Billing Code Overview
HCPCS Level II code P9012 represents cryoprecipitate, each unit. This item is a blood product derived from plasma that contains concentrated clotting factors, typically used to treat patients with hypofibrinogenemia, von Willebrand disease, or other coagulopathies.
-
Service type: Blood product transfusion supply
-
Typical site of service: Hospital inpatient, hospital outpatient, ambulatory surgical center, and transfusion centers where blood products are administered
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult inpatient with active bleeding or at high risk for bleeding due to hypofibrinogenemia, disseminated intravascular coagulation (DIC), massive transfusion, or congenital fibrinogen deficiency who requires transfusion support. Cryoprecipitate (P9012, cryoprecipitate, each unit) is prepared by thawing frozen plasma and pooling the cold-insoluble precipitate rich in fibrinogen, factor VIII, von Willebrand factor, and factor XIII. Clinical workflow: the ordering clinician documents an indication (for example, fibrinogen <100 mg/dL with bleeding), the transfusion service verifies crossmatch and product availability, the blood bank issues thawed cryoprecipitate units, bedside nursing performs patient identification and administers the product, and transfusion monitoring and post-transfusion fibrinogen levels are obtained as indicated. Typical sites of service include the inpatient hospital ward, intensive care unit, emergency department, and operating room during perioperative or trauma care. Patient monitoring includes vital signs, signs of transfusion reaction, and laboratory assessment of coagulation parameters after administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard billing when no modifier applies |